Philip Morris (PM) Stock Forecast & Price Target

Philip Morris Intl is well-positioned for future growth due to its strong portfolio of combustible and smoke-free products, pending FDA approval for new products such as ZYN Ultra, and its track record of successful brand building. Transitory impacts and tough comps may slow growth in the short-term, but the company's investments in new products and emerging markets are expected to drive positive consolidated volume performance and HSD-LDD adj. EPS in the medium term. Potential upside drivers include further success in the smoke-free category and potential FDA approval for IQOS PMTA in the US. However, there are risks to the target, including potential market share erosion and unforeseen compliance risk with the FDA.

Philip Morris Intl is facing potential upside drivers as they dominate the smoke-free market with their IQOS and Zyn brands, and their total addressable market expands internationally. However, despite their bullish case assumptions and raising their EPS estimates, there are potential risks in their bear case, such as increased competition in nicotine pouches and unforeseen regulatory hurdles that could impact their overall performance and earnings. This, along with a lower price target, leads to a negative outlook on the company.